![Sun Park](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Sun Park
Directeur Financier/CFO chez
TENET HEALTHCARE CORPORATION
Fortune : 3 M $ au 31/05/2026
Profil
Sun Park is Chief Financial Officer & Executive Vice President at Tenet Healthcare Corp.
since 2024.
Former positions include Director at Profarma Distribuidora de Produtos Farmaceuticos SA, Vice President & Head-Corporate Strategy at MedImmune LLC, Vice President-Corporate Strategy at AstraZeneca PLC from 2011 to 2012, Principal at Charterhouse Group, Inc., Executive VP-Strategy & Business Development at Cencora, Inc. from 2017 to 2018, and Analyst-Healthcare Investment Banking at Merrill Lynch & Co., Inc. Education includes graduate studies at The Johns Hopkins University and undergraduate studies at Yale University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 02/03/2026 | 19 438 ( 0,02 % ) | 3 M $ | 31/05/2026 |
Postes actifs de Sun Park
| Sociétés | Poste | Début |
|---|---|---|
| TENET HEALTHCARE CORPORATION | Directeur Financier/CFO | 01/01/2024 |
Anciens postes connus de Sun Park
| Sociétés | Poste | Fin |
|---|---|---|
| ASTRAZENECA PLC | Corporate Officer/Principal | 01/11/2012 |
| PROFARMA DISTRIBUIDORA DE PRODUTOS FARMACÊUTICOS S.A. | Directeur/Membre du Conseil | - |
Merrill Lynch & Co., Inc.
 Merrill Lynch & Co., Inc. Investment ManagersFinance Provides wealth management, securities trading and sales, corporate finance and investment banking services | Corporate Officer/Principal | - |
Charterhouse Group, Inc.
 Charterhouse Group, Inc. Investment ManagersFinance Charterhouse Group focuses on actively acquiring and managing middle-market companies in the business services, healthcare services and consumer products and services sectors. The firm seeks to invest in established, middle-market businesses with enterprise values of $50 million to $300 million through a variety of private equity transactions. While their concentration is on buyouts and build-ups, they also pursue growth capital financing opportunities. In addition, Charterhouse always considers prospective platform investments where the enterprise value is initially less than $50 million if the company is well-positioned for rapid growth through a build-up strategy in which add-on acquisitions are identifiable and achievable within the specific industry. In addition, in select instances the firm participates in larger transactions through co-investments with their limited partners, strategic corporate partners or with other financial investors where they are able to utilize one of their 'Charterhouse Entrepreneurs' to play a significant management or board director role. Currently, Charterhouse also sources a significant number of opportunities to make minority preferred stock investments in entrepreneur-owned, closely-held and sponsor-controlled deals, as well as in public entities. The firm is interested in exploring these types of non-control situations, with emphasis on situations in which high-quality companies are unable to tap the strained financial markets. Charterhouse generally seeks to invest at least $20 million in such opportunities. When considering investment opportunities, Charterhouse typically looks for the following: (1) superior, highly motivated management teams with proven track records of success in the same or within a related industry (2) favorable industry dynamics that will support revenue and earnings growth (3) leading positions in a sizable or rapidly growing and/or shifting market (4) sustainable competitive advantages such as brand recognition or proprietary products, services, processes or customer relationships (5) scalable business models and (6) the ability to exert significant board influence or control. The firm seeks to invest in middle-market businesses through a variety of private equity transactions including buyouts, buildups and growth capital. They look for companies with enterprise value between $75 million and $300 billion. They always consider smaller investments and they participate in larger transactions through co-investments with their limited partner base or through other strategic relationships. | Corporate Officer/Principal | - |
MedImmune LLC
 MedImmune LLC Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Corporate Officer/Principal | - |
Formation de Sun Park
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
26
Relations au 1er degré
9
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
MedImmune LLC
MedImmune LLC Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Tenet Healthcare Corp.
 Tenet Healthcare Corp. Hospital/Nursing ManagementHealth Services Provides health care services | Health Services |
AstraZeneca PLC
 AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Charterhouse Group, Inc.
Charterhouse Group, Inc. Investment ManagersFinance Charterhouse Group focuses on actively acquiring and managing middle-market companies in the business services, healthcare services and consumer products and services sectors. The firm seeks to invest in established, middle-market businesses with enterprise values of $50 million to $300 million through a variety of private equity transactions. While their concentration is on buyouts and build-ups, they also pursue growth capital financing opportunities. In addition, Charterhouse always considers prospective platform investments where the enterprise value is initially less than $50 million if the company is well-positioned for rapid growth through a build-up strategy in which add-on acquisitions are identifiable and achievable within the specific industry. In addition, in select instances the firm participates in larger transactions through co-investments with their limited partners, strategic corporate partners or with other financial investors where they are able to utilize one of their 'Charterhouse Entrepreneurs' to play a significant management or board director role. Currently, Charterhouse also sources a significant number of opportunities to make minority preferred stock investments in entrepreneur-owned, closely-held and sponsor-controlled deals, as well as in public entities. The firm is interested in exploring these types of non-control situations, with emphasis on situations in which high-quality companies are unable to tap the strained financial markets. Charterhouse generally seeks to invest at least $20 million in such opportunities. When considering investment opportunities, Charterhouse typically looks for the following: (1) superior, highly motivated management teams with proven track records of success in the same or within a related industry (2) favorable industry dynamics that will support revenue and earnings growth (3) leading positions in a sizable or rapidly growing and/or shifting market (4) sustainable competitive advantages such as brand recognition or proprietary products, services, processes or customer relationships (5) scalable business models and (6) the ability to exert significant board influence or control. The firm seeks to invest in middle-market businesses through a variety of private equity transactions including buyouts, buildups and growth capital. They look for companies with enterprise value between $75 million and $300 billion. They always consider smaller investments and they participate in larger transactions through co-investments with their limited partner base or through other strategic relationships. | Finance |
Cencora, Inc.
 Cencora, Inc. Medical DistributorsDistribution Services Distributes pharmaceutical products | Distribution Services |
Profarma Distribuidora de Produtos Farmaceuticos SA
 Profarma Distribuidora de Produtos Farmaceuticos SA Medical DistributorsDistribution Services Distributes pharmaceutical products | Distribution Services |
The Johns Hopkins University
 The Johns Hopkins University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Merrill Lynch & Co., Inc.
Merrill Lynch & Co., Inc. Investment ManagersFinance Provides wealth management, securities trading and sales, corporate finance and investment banking services | Finance |
